Pharsight

Firdapse is owned by Catalyst Pharms.

Firdapse contains Amifampridine Phosphate.

Firdapse has a total of 6 drug patents out of which 0 drug patents have expired.

Firdapse was authorised for market use on 28 November, 2018.

Firdapse is available in tablet;oral dosage forms.

Firdapse can be used as method of treating lambert-eaton myasthenic syndrome with amifampridine.

Drug patent challenges can be filed against Firdapse from 2022-11-28.

The generics of Firdapse are possible to be released after 25 February, 2037.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11274332	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US11274331	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US11268128	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US11060128	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)
US10793893	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	May, 2034 (11 years from now)
US10626088	CATALYST PHARMS	Determining degradation of 3,4-diaminopyridine	Feb, 2037 (13 years from now)